|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The initial characterization of tumor-suppressing kinases- in particular members of the protein kinase C (PKC) family, MKK4 of the mitogen-activated protein kinase kinase family, and DAPK3 of the death-associated protein kinase family- laid the foundation for bioinformatic approaches that enable the identification of other tumor-suppressing kinases.
|
30548122 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consequently, selective activation of the MEKK4-MKK4-p38 signaling axis by triptonide activated tumor suppressor p21 and inhibited CDK3 expression, resulting in cancer cell cycle arrest at G2/M phase and marked inhibition of pancreatic cancer cell tumorigenic capability in vitro and tumor growth in xenograft mice.
|
31075266 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor cytoplasmic MKK4 and MKK7 expressions were significantly negatively associated with histologic grade.
|
30537492 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings also suggest that MAP3K1 and MAP2K4 are potential drug targets in combination with MEK inhibitors, in spite of the fact that they are encoded by tumor suppressor genes.
|
29795445 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine the role of the MEKK1/SEK1/JNK1/AP-1 pathway in the action of Xihuang pill (XHP) in reducing regulatory T (Treg) cell numbers in the tumor microenvironment in a 4T1 mouse breast cancer model, and to clarify the anti-tumor mechanism of XHP in breast cancer.
|
29710529 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The experimentally observed targets of miR-141 include the tumor-suppressor gene mitogen-activated protein kinase kinase 4 (MAP2K4).
|
28454307 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
|
28319306 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MKK4 is a candidate tumor suppressor, which acts as a critical mediator of Epstein-Barr Virus (EBV)-induced c-Jun N-terminal kinase (JNK) activation.
|
21702039 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MKK4 has been suggested as a tumor suppressor.
|
22526163 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To confirm that MKK4 expression related to tumor suppress function, we used two independent but complementary approaches.
|
21487811 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We screened for mutations in MAP2K4 using High Resolution Melt analysis of 149 primary ovarian tumors and methylation at the promoter using Methylation-Specific Single-Stranded Conformation Polymorphism analysis of 39 tumors.
|
21575258 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing PPARγ2 levels.
|
21896780 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To confirm that MKK4 expression is related to tumor suppressor function, we used 2 independent but complementary approaches.
|
21372598 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Located on 17p adjacent to the TP53 gene, MKK4 is one of the most consistently mutated genes across tumor types, and is located on one of the most frequently lost arms in the human genome.
|
16721048 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This multivariate analysis revealed a 5-fold increased risk of death (P<.001) in patients whose primary tumors were MKK4-negative.
|
17116802 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For example, MKK4, a tumor suppressor gene distinguished by a remarkably consistent mutational rate across diverse tumor types and an unusually high rate of loss of heterozygosity, has the surprisingly low rate of genetic inactivation of only approximately 5%.
|
16740690 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mRNA expression of Nm23, KISS1, KAI1, BRMS1, and Mkk4 in fresh frozen tissue samples of brain metastases from ductal invasive breast cancer specimens was examined in relation to primary tumors.
|
15592684 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MKK4, located in close proximity to p53 gene, is thought to be a tumor suppressor and a metastasis suppressor gene.
|
15184866 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 0.8 Mb-region between D17S1525 and MAP2K4 in 17p12 proved to be commonly amplified in these tumors.
|
12645656 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The conclusion that JNK can act as a tumor suppressor is consistent with the presence of loss-of-function mutations in JNK pathway components (Jnk3 and Mkk4) in human tumors.
|
12734425 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma.
|
12376211 |
2002 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To investigate the role of germ-line mutations in the etiology of pancreatic cancer, we have analyzed samples from patients with pancreatic cancer enrolled in the NFPTR for mutations in four tumor suppressor candidate genes: (a) MAP2K4; (b) MADH4; (c) ACVR1B; and (d) BRCA2 by direct sequencing of constitutional DNA.
|
12097290 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The exception is breast cancer, where genetic inactivation in 3 of 22 (15%) cell lines had suggested that the mutational involvement of MAP2K4 might be accentuated in this tumor type.
|
11754110 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No differences in MKK4/SEK1 gene expression or in the 41 other metastasis and tumor suppressor genes were found in A375 melanoma cells cultured in Tyr- and Phe-deprived media.
|
11694646 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Coexistent mutations of other tumor suppressor genes in MKK4-deficient tumors suggest that MKK4 may participate in a tumor suppressive signaling pathway distinct from DPC4, p16, p53, and BRCA2.
|
9622070 |
1998 |